WO2015022560A8 - Stable pharmaceutical composition containing bisoprolol and ramipril - Google Patents
Stable pharmaceutical composition containing bisoprolol and ramipril Download PDFInfo
- Publication number
- WO2015022560A8 WO2015022560A8 PCT/HU2014/000072 HU2014000072W WO2015022560A8 WO 2015022560 A8 WO2015022560 A8 WO 2015022560A8 HU 2014000072 W HU2014000072 W HU 2014000072W WO 2015022560 A8 WO2015022560 A8 WO 2015022560A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ramipril
- composition containing
- pharmaceutical composition
- stable pharmaceutical
- containing bisoprolol
- Prior art date
Links
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002781 bisoprolol Drugs 0.000 title abstract 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 title abstract 2
- 229960003401 ramipril Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a combination composition containing ramipril and bisoprolol and preparation thereof. The active ingredients are separated from each other in the composition.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201690395A EA033291B1 (en) | 2013-08-16 | 2014-08-15 | Dosage unit comprising ramipril and bisoprolol hemifumarate, process for the preparation thereof and method of treating hypertension |
HU1600414A HU231052B1 (en) | 2013-08-16 | 2014-08-15 | Stable pharmaceutical composition containing bisoprolol and ramipril |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1300496A HUP1300496A2 (en) | 2013-08-16 | 2013-08-16 | Stable pharmaceutical composition |
HUP1300496 | 2013-08-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015022560A1 WO2015022560A1 (en) | 2015-02-19 |
WO2015022560A8 true WO2015022560A8 (en) | 2015-05-14 |
Family
ID=89991232
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2014/000072 WO2015022560A1 (en) | 2013-08-16 | 2014-08-15 | Stable pharmaceutical composition containing bisoprolol and ramipril |
PCT/HU2014/000071 WO2015022559A1 (en) | 2013-08-16 | 2014-08-15 | Pharmaceutical composition containing rosuvastatin and ramipril |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2014/000071 WO2015022559A1 (en) | 2013-08-16 | 2014-08-15 | Pharmaceutical composition containing rosuvastatin and ramipril |
Country Status (3)
Country | Link |
---|---|
EA (1) | EA033291B1 (en) |
HU (2) | HUP1300496A2 (en) |
WO (2) | WO2015022560A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3501502A1 (en) * | 2017-12-20 | 2019-06-26 | Midas Pharma GmbH | Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin |
EP4103158B1 (en) | 2020-02-10 | 2024-09-04 | Adamed Pharma S.A. | Composition comprising ramipril and indapamide |
CN115068434B (en) * | 2022-08-03 | 2023-05-09 | 昆山龙灯瑞迪制药有限公司 | Preparation method of ramipril tablet |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19575012I2 (en) | 1980-10-23 | 2002-01-24 | Schering Corp | Carboxyalkyl dipeptides Process for their preparation and medicaments containing them |
DE3226768A1 (en) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF |
DE3739690A1 (en) | 1987-11-24 | 1989-06-08 | Hoechst Ag | STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS |
US20030215526A1 (en) | 2002-03-08 | 2003-11-20 | Scott Stofik | Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
WO2003092729A1 (en) * | 2002-05-03 | 2003-11-13 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
DK1635792T3 (en) | 2003-06-26 | 2009-06-15 | Teva Pharma | Stable pharmaceutical compositions of 2-aza-bicyclo-3.3.0-octane-3-carboxylic acid derivatives |
EP1694308A1 (en) | 2003-10-30 | 2006-08-30 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
WO2005067887A2 (en) | 2004-03-24 | 2005-07-28 | Actavis Group | Formulations of ramipril |
CA2586547A1 (en) | 2004-11-05 | 2006-05-11 | King Pharmaceuticals Research & Development, Inc. | Stabilized individually coated ramipril particles, compositions and methods |
EP1948136A1 (en) * | 2005-11-07 | 2008-07-30 | King Pharmaceuticals Research and Development, Inc. | Compositions of stabilized ramipril in combination with another active agent |
CN100374462C (en) | 2005-11-21 | 2008-03-12 | 大连帝恩生物工程有限公司 | Gerobriecin pancrease glucagon peptidel (SGLP-1), its preparation and use |
US20070232680A1 (en) | 2006-04-04 | 2007-10-04 | Vijayabhaskar Bolugoddu | Preparation of ramipril and stable pharmaceutical compositions |
RU2008145115A (en) | 2006-04-19 | 2010-05-27 | Тева Фармасьютикл Индастриес Лтд. (Il) | STABLE PHARMACEUTICAL COMPOSITIONS OF PRODUCTION COMPOUNDS OF 2-AZA-Bicyclo [3.3.0] -OKTAN-3-CARBONIC ACID |
CA2653382A1 (en) | 2006-06-30 | 2008-01-03 | Alphapharm Pty Ltd | A stabilised composition comprising ace inhibitors |
US20110086092A1 (en) | 2006-08-08 | 2011-04-14 | Accu-Break Technologies, Inc. | Pharmacuetical tablets containing a plurality of active ingredients |
WO2008065485A2 (en) | 2006-10-19 | 2008-06-05 | Torrent Pharmaceuticals Limited | Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor |
SI2120878T1 (en) | 2007-02-09 | 2014-12-31 | Alphapharm Pty Ltd | A dosage form containing two active pharmaceutical ingredients in different physical forms |
WO2008132756A1 (en) | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
HU230877B1 (en) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stable pharmaceutical combination |
EP2272874A1 (en) | 2009-07-10 | 2011-01-12 | CSL Behring GmbH | Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
CN101612403A (en) | 2009-08-13 | 2009-12-30 | 王丽燕 | The pharmaceutical composition that contains calcium antagonist, ACE inhibitor and statins |
US20150094345A1 (en) | 2012-02-17 | 2015-04-02 | Egis Gyogyszergyar Zrt. | Pharmaceutical formulation having improved stability |
-
2013
- 2013-08-16 HU HU1300496A patent/HUP1300496A2/en not_active Application Discontinuation
-
2014
- 2014-08-15 HU HU1600414A patent/HU231052B1/en unknown
- 2014-08-15 WO PCT/HU2014/000072 patent/WO2015022560A1/en active Application Filing
- 2014-08-15 EA EA201690395A patent/EA033291B1/en not_active IP Right Cessation
- 2014-08-15 WO PCT/HU2014/000071 patent/WO2015022559A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
HUP1600414A2 (en) | 2016-09-28 |
WO2015022559A1 (en) | 2015-02-19 |
HU231052B1 (en) | 2020-02-28 |
HUP1300496A2 (en) | 2015-03-02 |
WO2015022560A1 (en) | 2015-02-19 |
EA201690395A1 (en) | 2016-07-29 |
EA033291B1 (en) | 2019-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285390A (en) | Arylquinazolines, their preparation and pharmaceutical compositions containing them | |
CA2894892A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
IL235767A (en) | Substituted pyrrolidines, pharmaceutical compositions comprising the same and uses thereof | |
PH12015501096A1 (en) | Composition for immediate and extended release | |
PH12015502755A1 (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
EP2978423A4 (en) | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it | |
EP3067059A4 (en) | Pharmaceutical composition for preventing or treating thyroid diseases, containing lonicera caerulea l. var. edulis fruit extract as active ingredient | |
EP2978420A4 (en) | Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it | |
IL233825A (en) | 1h-indazole-3-carboxamide compounds, compositions comprising them and uses thereof in the preparation of medicaments | |
WO2014179567A3 (en) | Methods and compositions for treating beta-thalassemia and sickle cell disease | |
MX2016001422A (en) | Pharmaceutical compositions of fingolimod. | |
WO2015092810A3 (en) | Amorphous form of idelalisib | |
PH12014502856A1 (en) | Solid pharmaceutical preparation containing levothyroxine | |
IL272806A (en) | Boronic acid derivatives, their preparation and pharmaceutical compositions containing them | |
IL280376A (en) | Boronic acid derivatives, their preparation and pharmaceutical compositions containing them | |
MX2015005762A (en) | Co-micronisation product comprising ulipristal acetate. | |
EP2871187A4 (en) | Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
EP2978421A4 (en) | Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it | |
WO2015022560A8 (en) | Stable pharmaceutical composition containing bisoprolol and ramipril | |
MX357704B (en) | O/w-emulsion-type topical pharmaceutical compositions containing a retinoid. | |
WO2014133811A3 (en) | Compounds from invasive salvinias and methods of using the same | |
WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
WO2015044434A3 (en) | Fluor-9-methyl-β-carbolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14777376 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201690395 Country of ref document: EA |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14777376 Country of ref document: EP Kind code of ref document: A1 |